HEICO (HEI-A) Forms $60.90 Double Top; 2 Analysts Bullish Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Among 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Regulus Therapeutics had 7 analyst reports since January 5, 2018 according to SRatingsIntel. Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Thursday, February 8. Wedbush has “Buy” rating and $4.0 target. The firm has “Hold” rating given on Tuesday, March 27 by FBR Capital. The firm has “Buy” rating by Wedbush given on Monday, March 12. The company was maintained on Thursday, May 17 by Wedbush. On Thursday, March 8 the stock rating was maintained by BMO Capital Markets with “Market Perform”. See Regulus Therapeutics Inc. (NASDAQ:RGLS) latest ratings:

17/05/2018 Broker: Wedbush Rating: Buy New Target: $3.0000 Maintain
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On

HEICO Corporation (HEI-A) formed double top with $64.55 target or 6.00% above today’s $60.90 share price. HEICO Corporation (HEI-A) has $7.04 billion valuation. The stock increased 1.36% or $0.82 during the last trading session, reaching $60.9. About 103,742 shares traded. HEICO Corporation (NYSE:HEI.A) has risen 52.26% since June 29, 2017 and is uptrending. It has outperformed by 39.69% the S&P500.

Another recent and important Regulus Therapeutics Inc. (NASDAQ:RGLS) news was published by Nasdaq.com which published an article titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $67.93 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart